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Original Article
INTRODUCTION
In 2008, with an estimated 263,000 new cases, oral (including 
lip) squamous cell carcinoma (SCC) ranked as the 15th most 
common cancer worldwide when the global incidence and relat-
ed mortality of 27 malignancies was estimated for 182 countries 
by the International Agency for Research on Cancer as part of 
the GLOBOCAN scheme [1]. The most common site of intraoral 
SCC is the tongue, which accounts for around 40% of all cases 
involving the oral cavity proper.
 Despite advances in surgery (including reconstructive tech-
niques) and radiotherapy and chemotherapy, the five-year sur-
vival rate for oral cancer has not improved significantly over the 
past several decades and it is still around 50% to 55%. There is 
an undeniable need for novel, more effective diagnostic and ther-
apeutic strategies to improve the overall survival of patients with 
oral SCC, particularly in advanced cases. Very recent research 
has focused on targeted molecular therapy, immunotherapy, and 
latent/residual tumor cell ablation. Although many promising 
therapies have been tested, only anti-epidermal growth factor 
receptor (anti-EGFR) therapy has been approved by the U.S. 
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Objectives. Phosphorylated (activated) STAT3 (pSTAT3) is a regulator of numerous genes that play an essential part in the 
onset, development and progression of cancer; it is involved in cell proliferation and preventing apoptosis, and in in-
vasion, angiogenesis, and the evasion of immune surveillance. This study aimed mainly to investigate the potential 
prognostic role of pSTAT3 expression in oral tongue squamous cell carcinoma (SCC). 
Methods. Phospho-ser727 STAT3 immunolabeling was correlated with prognostic parameters in 34 consecutive cases of 
pT1–T2 tongue SCCs undergoing primary surgery. Computer-based image analysis was used for the immunohisto-
chemical reactions analysis. 
Results. Statistical analysis showed a difference in disease-free survival (DFS) when patients were stratified by pN status 
(P=0.031). Most tumors had variable degrees (mean±SD, 80.7%±23.8%) of intense nuclear immunoreaction to 
pSTAT3. Our findings rule out any significant association of serine-phosphorylated nuclear STAT3 expression with 
tumor stage, grade, lymph node metastasis, recurrence rate, or DFS.
Conclusion. In spite of these results, it is worth further investigating the role of pSTAT3 (serine- and tyrosine-pSTAT3) in 
oral tongue SCC in larger series because preclinical models are increasingly showing that several anticancer strategies 
would benefit from STAT3 phosphorylation inhibition.
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Food and Drug Administration in recent years for use in SCCs 
of the head and neck.
 STAT3 is a member of the STAT family that takes part in the 
normal cellular responses to cytokines and growth factors, such 
as transcription factors. STAT3 occurs in the cytoplasm under 
basal conditions and is activated as a consequence of the ligand-
mediated receptor activation induced by Janus tyrosine kinases 
or growth factors. It seems that, while STAT2, STAT4, and STAT6 
are only activated under normal conditions, STAT1, STAT3, and 
STAT5 would appear to have an important part to play in cancer 
(STAT1 as a tumor suppressor, and STAT3, and STAT5 as onco-
genes) [2]. In normal cells, the ligand-dependent activation of the 
STATs is a transient process, lasting from a few minutes to sever-
al hours. In tumors, STAT proteins remain persistently phosphor-
ylated, and consequently activated: phosphorylated STAT3 
(pSTAT3) dimerizes and moves to the nucleus, regulating the 
transcription of target genes. There are reports of STAT3 being 
constitutively activated in lymphomas and in numerous primary 
cancers affecting the prostate, breast, lung, colon, liver or pancre-
as, and in head and neck carcinomas too [3-5]. The C-terminal 
transactivation domain of STAT3 has an important role in its ac-
tivation through a tyrosine residue at position 705 and a serine 
residue at position 727 [2]. In particular, phosphorylation of the 
ser-727 site by several serine kinases, such as mammalian target 
of rapamycin, protein kinase C (PKC) delta, cyclin-dependent ki-
nase 5, and PKC-ε, determines the maximal transcriptional activ-
ity of STAT3 [4]. pSTAT3 regulates many of the genes that play a 
part in a cancer’s initiation, development, and progression, affect-
ing cell proliferation, interfering with apoptosis, and supporting 
invasion, angiogenesis, and immune surveillance evasion [2,4]. It 
has also recently been reported that, in head and neck carcino-
ma, pSTAT3 is a downstream effector of EGFR, interleukin (IL) 6, 
and the Src family of kinases [6,7]. 
 The aim of this study was to conduct a preliminary (because 
of the retrospective setting and the limited number of consid-
ered cases) investigation into the potentially prognostic role of 
pSTAT3 expression in a series of consecutive cases of pT1–T2 of 
primary oral tongue SCC. This is the first time anti–phospho-
ser727 STAT3 antibody has been used in oral tongue SCC.
MATERIALS AND METHODS
Patients
The study was approved by the Padova University Otolaryngol-
ogy Section’s Ethical Committee. It involved 34 consecutive 
cases (25 male patients, 9 female ones; mean age, 66.2±12.2 
years) of primary pT1–T2 tongue SCC. Twenty-eight out of 34 
cases had been previously evaluated for angiogenin, endoglin, 
and Mib-1 expressions [8]. Upper aero-digestive tract endoscopy 
and neck ultrasonography (with or without fine needle aspira-
tion cytology), contrast-enhanced computed tomography (CT) 
or/and magnetic resonance imaging of the head and neck, chest 
X-rays, and liver ultrasonography were performed in all patients.
 After primary partial glossectomy with unilateral or bilateral 
cervical lymph node dissection (at the Otolaryngology Section 
of Padova University), the final histopathology report confirmed 
that all patients had negative surgical margins. According to the 
TNM classification of the International Union Against Cancer 
(Union Internationale Contre le Cancer) and the American Joint 
Committee on Cancer (7th edition) [9], the pathological stage of 
the primary tongue lesions (pT) was T1 in 16 cases, and T2 in 
18; the regional lymph nodes were pathologically staged (pN) as 
N0 in 26 cases and N+ in eight. Twenty-nine patients underwent 
elective neck dissection, five therapeutic neck dissection. There 
were no cases of distant metastases. The pathological grade was 
G1 in 12 cases, G2 in 13, and G3 in nine. Median hospitaliza-
tion time was 9 days. Eight patients underwent postoperative 
radiotherapy (PORT) according to current guidelines [10]. The 
PORT total dose was 60 Gy (conventional fractionation 2 Gy/
fraction, once a day). The treatment time was 30 days.
 The clinical follow-up schedule (adjustable to patients’ individ-
ual characteristics) was as follows: (1) once a month for the 1st 
year after treatment; (2) every 2 months in the 2nd year; (3) ev-
ery 3 months in the 3rd year; (4) every 4 months in the 4th year; 
(5) every 6 months in the 5th year; and (6) every 12 months 
thereafter. Neck ultrasonography and chest X-rays were also per-
formed at least yearly. Contrast-enhanced CT of the neck, total 
body positron emission tomography, chest CT, and liver ultraso-
nography were repeated as necessary. 
Immunohistochemistry
Immunohistochemical reactions were obtained on sections 4- to 
5-μm-thick obtained from the 34 formalin-fixed and paraffin-em-
bedded tumor samples. No cases were excluded because of the 
lack of representative carcinoma tissue. All immunohistochemical 
stains were handled automatically (Bond maX, Menarini, Flor-
ence, Italy), as described elsewhere [11], using an anti–phospho-
ser727 STAT3 primary antibody (rabbit polyclonal, SAB Signal-
way Antibody, Pearland, TX, USA; working dilution 1:200, 30 
minutes, citrate buffer), according to the manufacturer’s instruc-
tions. The prepared sections were lightly counterstained with he-
matoxylin. Since their constitutive STAT3 activation [12], breast 
carcinoma samples served as positive controls, according to pro-
ducer’s suggestions, and sections incubated with no primary anti-
body as negative controls. For each slide, nuclear immunoreac-
tion in tumor cells was scored separately by two pathologists (FM 
and RC) on a four-tired scale based on the staining intensity: 0, 
absent staining; 1+, weak; 2+, moderate; and 3+, strong; as re-
ported elsewhere [6]; the pathologists were unaware of the pa-
tients’ prognosis.
Image analysis 
An image analysis (IA) workstation was used to assess nuclear 
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pSTAT3 expression in all samples. The system comprised a con-
ventional Zeiss Axioskop light microscope (Zeiss, Jena, Germa-
ny) with a color digital, Peltier-cooled video camera (MicroPub-
lisher 5.0 RTV, QImaging, Surrey, BC, Canada) that was connect-
ed to a PC with Image-Pro Plus software, Version 7 for Windows 
(Media Cybernetics Inc., Bethesda, MD, USA). Five areas of tu-
mor tissue or morphologically normal mucosa 1,378 μ×954 μ in 
size were always examined blindly with the aid of a 495-point 
sampling grid by that the program superimposed on images ac-
quired with a 50× field of view; the analysis relied on a tailored 
subroutine (Winrec, Immagini & Computer, Milano, Italy) that 
enabled the points intercepting the positive and negative areas to 
be identified and counted interactively. In compliance with ste-
reological best practice, the proportion of the area found positive 
was calculated as a percentage (%). 
Statistical analysis
Fisher exact test and the Mann-Whitney U-test were applied, as 
appropriate. For disease-free survival (DFS), we considered the 
months elapsing from when the treatment was completed up 
until there was a loco-regional recurrence. We used the log-rank 
test and Cox regression modeling to establish the DFS after 
stratifying patients in the light of the variables considered and 
the associated hazards. Considering the low number of consid-
ered cases, the median pSTAT3 nuclear expression value among 
SCCs was used as the threshold for the analyses. Statistical sig-
nificance was assumed for a P-value of <0.05, while values in 
the range of 0.05≤P<0.10 were considered as indicating a sta-
tistical trend. The STATA 8.1 (Stata Corp., College Station, TX, 
USA) was used for all analyses.
RESULTS
Patients’ clinical outcome
The average follow-up was 61.7±42.3 months (median, 56.0 
months). Twelve patients developed SCC recurrences (9 local and 
3 loco-regional) after a mean 34.6±33.6 months (median, 19 
months). The Mann-Whitney U-test ruled out any significant dif-
ference in the mean duration of the follow-up between patients 
with and without recurrent disease (P=0.88). In accordance with 
follow-up protocol, 22 patients showed no evidence of recurrent 
disease at last clinical control; on the other hand, 3 patients died 
of disease, and 9 of other causes. After grouping patients by 
whether or not their disease recurred after treatment, Fisher ex-
act test showed a difference in the distribution by lymph node 
status (pN0 vs. pN+, P=0.09, indicating a trend towards signifi-
cance), but not for pT (pT1 vs. pT2, P=0.29), or grade (G1 vs. 
G2–3, P<0.999). The hazard ratio for recurrence during the fol-
low-up considered was 4.5 times higher for pN+ patients, and 2.4 
times higher for pT2 cases. The log-rank test found a difference in 
DFS (in months) when patients were stratified by nodal status 
([pN0 vs. pN+, P=0.031]; One patient was staged as cN0 but re-
sulted pN+ [occult metastasis]) (Fig. 1) and pT (pT1 vs. pT2) 
(P=0.09, trend towards significance), but the same did not apply 
to grade (G1 vs. G2–3, P=0.86). 
pSTAT3 expression, nuclear staining intensity, and  
clinicopathological features of oral tongue SCC
The tongue SCCs covered the whole range from well to poorly 
differentiated neoplasms (Fig. 2A, B). The well differentiated tu-
mors featured keratinizing squamous epithelium with an abun-
dance of keratin pearls. In cases with a moderate to poor differ-
entiation, neoplastic cells with pronounced cytonuclear atypia 
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Fig. 1. Disease-free survival in oral tongue squamous cell carcinoma 
patients stratified by pN-status (pN0 vs. pN+).
A B
C D
Fig. 2. Representative images of the series considered. (A) The mi-
crograph shows normal tongue epithelium (asterisk) adjacent to 
squamous cell carcinoma (double asterisk) (H&E). (B) In this mod-
erately-differentiated squamous cell carcinoma of the tongue, neo-
plastic cells infiltrating the muscle are arranged in large anastomos-
ing areas and form keratin pearls (H&E). (C) A squamous cell carci-
noma showing a strong, diffuse nuclear immunoreaction to pSTAT3 
(pSTAT3 immunohistochemistry). (D) This micrograph shows the ab-
sence of pSTAT3 expression in the well-differentiated tumor areas 
(asterisk), and strong, diffuse immunolabeling in the less differentiat-
ed areas (double asterisk) (pSTAT3 immunohistochemistry). 
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were arranged in large anastomosing areas with little or no sign 
of keratin pearls, or occasionally with formed cords. 
 pSTAT3 immunostaining in normal tongue mucosa was con-
sidered first with a view to determine its usual pattern of expres-
sion. pSTAT3 showed a basal to surface gradient in this stratified 
squamous epithelium: there was ample, strong nuclear labeling 
in the basal and spinous layers, while staining in the granular lay-
er was weak and scarce, and there was no immunoreaction in 
the keratin layer. In normal mucosa, IA measured a mean of 
30.4%±1.1% pSTAT3 immunohistochemically positive nuclei. 
Most of tumors extensively showed an intense nuclear immuno-
reaction to pSTAT3 (Fig. 2C). Overall, pSTAT3 expression was 
strong and diffuse in moderately and poorly differentiated tumor, 
but weak or absent in well differentiated areas, especially if kera-
tin pearls were abundant (Fig. 2D).
 All 34 oral tongue SCCs revealed some degree of pSTAT3 im-
munoreactivity: the intensity of this pSTAT3 nuclear reaction 
was classed as 1+ in six cases, 2+ in 12, and 3+ in 16. IA indicat-
ed a mean nuclear pSTAT3 expression of 80.7%±23.8%, in 
tongue carcinoma that was remarkably higher compared with of 
normal mucosa’s one (30.4%); the median expression value in 
carcinoma (90.0%) was used as threshold for the following anal-
yses.
 Statistical analysis excluded any significant difference in pSTAT3 
expression between pT1 SCCs and pT2 cases (Mann-Whitney U-
test, P=0.36), between those with pN0 and pN+ (Mann-Whitney 
U-test, P=0.40), and between patients with G1 and G2–3 dis-
ease (Mann-Whitney U-test, P=0.23). Table 1 shows the mean 
pSTAT3 expression emerging from IA in the various clinicopath-
ological groups of our sample of oral tongue SCC patients. The 
Mann-Whitney U-test found no significant relationships between 
the intensity of the pSTAT3 nuclear reaction and pT (P=0.23), 
lymph node status (P=0.25), or pathological grade (P=0.49). 
pSTAT3 expression and prognosis in oral tongue SCC
The Mann-Whitney U-test ruled out any significant difference in 
pSTAT3 expression between patients with and without recurrent 
disease (P=0.31). Cox regression model also excluded any sig-
nificant difference in DFS (in months) for different pSTAT3 ex-
pression levels in the oral tongue carcinoma cells (P=0.50). Our 
statistical analysis also confirmed that there was no significant as-
sociation between the intensity of the pSTAT3 nuclear reaction 
and disease recurrence rate (Mann-Whitney U-test, P=0.90) or 
DFS (log-rank, P=0.98).
DISCUSSION
Given that this was a preliminary investigation, the main strength 
of the study lies in the homogeneity of the series of patients con-
sidered, i.e., (1) they all had primary pT1–T2 oral tongue SCCs; 
(2) they underwent surgery performed consecutively by the 
same team; (3) pathological T and N staging was available for all 
cases; (4) only surgical specimens (not biopsies) of oral tongue 
SCC were assessed. In addition, the present study focused on the 
expression of serine-pSTAT3, which has been considerably less 
thoroughly investigated than tyrosine-pSTAT3 in head and neck 
SCC, and a computer-based IA system was used to ensure a 
highly accurate, precise, and reproducible analysis of the immu-
nostained slides. The main weaknesses of our investigation, on 
the other hand, concern the retrospective setting and the limited 
number of cases considered.
 From a conventional pathological viewpoint, pN stage corre-
lated significantly with prognosis (DFS) in the present series, as 
already reported extensively for oral tongue SCC. Local inva-
sion and spread to regional lymph nodes in the neck are com-
mon in oral SCC, facilitated by the carcinoma’s highly-invasive 
behavior and by the lymphatic drainage in the cervical region 
[13]. The tongue has a rich blood supply and lymphatic drain-
age, and this explains why up to 65 percent of patients with pri-
mary tongue lesions already have neck disease by the time they 
are diagnosed.
Table 1. Image analysis-measured pSTAT3 expression and disease-free survival (DFS) associated with classical pathological variables in oral 
tongue squamous cell carcinoma
Variable
No. of 
cases
No loco-regional 
recurrence
With loco-regional 
recurrence
DFS 
(month)
pSTAT3 nuclear expression (%) 
in tongue carcinoma cells
Hazard ratio for recurrence
Primary tongue lesions pT1 vs. pT2
4.5 times higher for pN+ 
(95% CI, 0.64–35.0; P=0.09)
   pT1 16 12 4 66.5±51.3 88.4±12.0
   pT2 18 10 8 39.6±28.6 73.9±29.1
Regional lymph nodes pN+ vs. pN0
2.4 times higher for pT2 
(95% CI, 0.45–14.0; P=0.29)
   pN0 26 19 7 57.9±45.4 84.4±18.8
   pN+ 8 3 5 33.8±27.1 68.6±32.9
Grade
   G1 12 9 3 54.8±37.5 87.5±16.4
   G2 13 7 6 56.2±52.4 80.6±21.3
   G3 9 6 3 43.2±32.3 71.8±31.4
Values are presented as mean±standard deviation.
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 STAT3 is a transcription factor with important roles in cancer 
formation and progression; it is involved in several cellular mech-
anisms, such as proliferation, inhibition of apoptosis, immune es-
cape, epithelial-mesenchymal transition, invasion, and angiogen-
esis [14,15]. In normal cells, STAT3 is transiently phosphorylated 
in response to several extracellular signals [16], but in a variety 
of cancers (including squamous carcinomas of the head and 
neck) it is constitutively activated, causing neoplastic cell trans-
formation (i.e., acting as an oncogene) [4,7,15,17-19]. Although 
STAT3 activation is not the only, nor even a specific molecular 
change in head and neck carcinogenesis, Grandis and colleagues 
demonstrated that it is very common and it occurs early, so it 
seems to be crucial to maintaining the neoplastic phenotype in 
this group of cancers [18-22]. Consistently with the above litera-
ture and with our previous findings in temporal bone SCCs [6], 
the tongue SCCs in our sample showed strong (intensity ≥2+ in 
28/34 cases) and diffuse nuclear pSTAT3 immunolabeling 
(mean±SD, 80.7%±23.8%; median, 90.0%). 
 Investigating the human oral SCC cell line MIKS81-5, Naher 
et al. [23] found that IL-22 induced a transient tyrosine phos-
phorylation of STAT3 (the change in serine phosphorylation was 
subtle); and IL-22 prompted a pSTAT3 translocation into the nu-
cleus. Tyrosine-pSTAT3 immune expression was examined by 
Seethala et al. [24] in two separate groups of patients with head 
and neck SCC (involving 61 and 69 cases), and they found 
pSTAT3 unrelated to clinical outcome in either group. When Ma-
cha et al. [25] studied 94 cases of oral SCC, however, they re-
ported that the DFS was significantly shorter for those with 
higher tyrosine-pSTAT3 levels in the nucleus than for cases not 
expressing nuclear pSTAT3; and judging from their statistical 
analysis, nuclear pSTAT3 was the most significant predictor of a 
poor prognosis. Our findings ruled out any association of serine-
phosphorylated nuclear STAT3 expression with tumor stage, 
grade, lymph node involvement, recurrence rate, or DFS. Zhao et 
al. [26] analyzed the baseline clinical characteristics of 80 lingual 
SCC patients vis-à-vis their STAT3 expression, finding that its 
expression correlated significantly with lymph node metastasis 
and disease stage. They also correlated STAT3 expression with 
prognosis in 39 patients, finding its expression significantly relat-
ed to carcinoma recurrence and death. There are notable differ-
ences between our own and the Zhao et al. [26] study, however, 
that can explain these conflicting results. Our series of tongue 
SCCs included only locally confined tumors (pT1 and pT2) and 
only a few cases (8/34) with lymph node disease, and this could 
have affected our results. We also analyzed a phosphorylated 
form of STAT3 (in serine 727, reported to be the more active 
form), ignoring the other variant (phospho-tyrosine 705 STAT3) 
evaluated by other authors. Since both kinds of phosphorylation 
appear to activate STAT3 (whether they do so alternately or con-
currently remains to be seen), leading to its dimerization and 
translocation in the nucleus, and consequently to the transcrip-
tion of its target genes, we cannot definitely rule out any pSTAT3 
involvement in tongue SCC. Finally, we considered only nuclear 
pSTAT3 immunolabeling as evidence of positivity (since pSTAT3 
acts as a transcription factor), and a very precise quantification 
method was used (IA). Rather than the limited number and the 
loco-regionally homogeneously extended tongue SCCs, the ma-
jor factor limiting our attempt to correlate pSTAT3 expression 
with the clinic-pathological variables was pSTAT3 uniformly in-
tense and widespread diffused immunostaining among the series. 
This indicates that probably other markers are involved in 
pSTAT3 activity, such as its coactivators CREB-binding Protein/
p300, APE1/Ref-1, and NCOA/Src1a, and should be analyzed 
together [4].
 Although our results suggest that pSTAT3 has no prognostic 
value, its strong and diffuse expression in tongue SCC remains 
intriguing. Different pathways (transforming growth factor-α/
EGFR, IL-6/gp130/Jak, Src, and nicotine) converge on pSTAT3, 
which might ultimately have a pivotal role in cell proliferation 
[18,19,27-30]. This abundance of activators could point to STAT3 
having a complementing oncogenic activity, and this would make 
it an ideal target to investigate for novel therapies. 
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